In last trading session, Regulus Therapeutics Inc (NASDAQ:RGLS) saw 2.2 million shares changing hands with its beta currently measuring 1.17. Company’s recent per share price level of $1.48 trading at $0.15 or 11.28% at ring of the bell on the day assigns it a market valuation of $96.95M. That closing price of RGLS’s stock is at a discount of -156.08% from its 52-week high price of $3.79 and is indicating a premium of 43.92% from its 52-week low price of $0.83. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.39 million shares which gives us an average trading volume of 458.39K if we extend that period to 3-months.
For Regulus Therapeutics Inc (RGLS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.33. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.22 in the current quarter.
Regulus Therapeutics Inc (NASDAQ:RGLS) trade information
Upright in the green during last session for gaining 11.28%, in the last five days RGLS remained trading in the green while hitting it’s week-highest on Wednesday, 03/12/25 when the stock touched $1.48 price level, adding 0.67% to its value on the day. Regulus Therapeutics Inc’s shares saw a change of -6.33% in year-to-date performance and have moved 9.63% in past 5-day. Regulus Therapeutics Inc (NASDAQ:RGLS) showed a performance of 23.33% in past 30-days. Number of shares sold short was 2.24 million shares which calculate 3.07 days to cover the short interests.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 50.96% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 46.10% while estimates for its earnings growth in next 5 years are of -0.36%.
Regulus Therapeutics Inc (NASDAQ:RGLS)’s Major holders
Insiders are in possession of 2.21% of company’s total shares while institution are holding 83.41 percent of that, with stock having share float percentage of 85.30%. Investors also watch the number of corporate investors in a company very closely, which is 83.41% institutions for Regulus Therapeutics Inc that are currently holding shares of the company. FEDERATED HERMES, INC. is the top institutional holder at RGLS for having 12.85 million shares of worth $22.94 million. And as of 2024-06-30, it was holding 19.9374 of the company’s outstanding shares.
The second largest institutional holder is RA CAPITAL MANAGEMENT, L.P., which was holding about 6.25 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.6952 of outstanding shares, having a total worth of $11.16 million.
On the other hand, Federated Hermes Kaufmann Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Oct 31, 2024 , the former fund manager was holding 7.88 shares of worth $11.66 million or 12.03% of the total outstanding shares. The later fund manager was in possession of 2.5 shares on Dec 31, 2024 , making its stake of worth around $3.7 million in the company or a holder of 3.82% of company’s stock.
